Scalper1 News
Biotech Theravance (THRX) and its big-pharma partner GlaxoSmithKline (GSK) released positive data on a trial of their drug for asthma Friday, sending both stocks up in the stock market today. The companies said the phase-three trial met its primary endpoint of bringing a statistically significant improvement in lung function after 12 weeks of treatment. The drug is a combination of fluticasone furoate, a steroid that Glaxo sells separately as the Scalper1 News
Scalper1 News